Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01567709
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:57.687002+00:00
Published At
2018-04-11T00:00:00+00:00
Record Updated At
2018-04-11
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Adult B Acute Lymphoblastic Leukemia", "Adult T Acute Lymphoblastic Leukemia", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-Cell Lymphoma", "Chronic Lymphocytic Leukemia", "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Hepatosplenic T-Cell Lymphoma", "Intraocular Lymphoma", "Lymphomatous Involvement of Non-Cutaneous Extranodal Site", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Nodal Marginal Zone Lymphoma", "Primary Cutaneous B-Cell Non-Hodgkin Lymphoma", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-Cell Leukemia/Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides and Sezary Syndrome", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Small Intestinal Lymphoma", "Splenic Marginal Zone Lymphoma", "T-Cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Waldenstrom Macroglobulinemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-04-11"
protocolSection.identificationModule.nctId
"NCT01567709"
protocolSection.identificationModule.officialTitle
"Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Adult B Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Adult T Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Anaplastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Angioimmunoblastic T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (protocolSection.conditionsModule.conditions)
  • Hepatosplenic T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Intraocular Lymphoma (protocolSection.conditionsModule.conditions)
  • Lymphomatous Involvement of Non-Cutaneous Extranodal Site (protocolSection.conditionsModule.conditions)
  • Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Nodal Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • Primary Cutaneous B-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Grade III Lymphomatoid Granulomatosis (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Immunoblastic Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Lymphoblastic Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Adult T-Cell Leukemia/Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Grade 1 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Grade 2 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Grade 3 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Mycosis Fungoides and Sezary Syndrome (protocolSection.conditionsModule.conditions)
  • Recurrent Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Hairy Cell Leukemia (protocolSection.conditionsModule.conditions)
  • Small Intestinal Lymphoma (protocolSection.conditionsModule.conditions)
  • Splenic Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • T-Cell Large Granular Lymphocyte Leukemia (protocolSection.conditionsModule.conditions)
  • Testicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Waldenstrom Macroglobulinemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.